(1 - 13 von 15
)
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC:...
www.investegate.co.uk
Investegate announcements from AstraZeneca PLC, Trastuzumab deruxtecan achieves ORR of 60.9%
Daiichi Sankyo: The CEO who capped a $37 billion recovery with...
economictimes.indiatimes.com
... cancer drugs, overhauling operations, making acquisitions and hiring Antoine Yver, who ran the oncology unit at AstraZeneca, in April
Daiichi Sankyo appoints Antoine Yver as Global Head ...www.manufacturingchemist.com › ...
www.manufacturingchemist.com
Daiichi Sankyo has hired Antoine Yver as Global Head, Oncology Research and Development. In this newly created role, Dr Yver will report to ...
(pexidartinib) for the Treatment of Select Patients with TGCT, a ...fdahealthnews.com › stories ›
fdahealthnews.com
... systemic treatment options," said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, ...
Daiichi Sankyo & Gustave Roussy collaborate for oncology research
www.biospectrumasia.com
Daiichi Sankyo & Gustave Roussy has announced a research collaboration for the development of DS and patritumab deruxtecan.
Daiichi Sankyo Starts First-in-Human Phase I/II Study Evaluating...
www.adcreview.com
Daiichi Sankyo Starts First-in-Human Phase I/II Study Evaluating DS » ADC Review
FDA Grants Priority Review for Trastuzumab Deruxtecan to Treat...
www.oncnursingnews.com
The FDA has granted a priority review for Trastuzumab Deruxtecan to treat HER2-positive metastatic breast cancer based on the results from two new studies.
FDA rejects quizartinib for acute myeloid leukemia subtype
www.healio.com
“Daiichi Sankyo is evaluating the complete response letter and will determine next steps in the U.S.,” Antoine Yver, MD, MSc, executive vice ...
Global News | CenterWatch
www.centerwatch.com
CenterWatch provides a variety of clinical research products and services: including clinical trials and results, drug approvals, study grants, news and...
One hit, one miss as FDA panel votes on Daiichi’s cancer drugs -...
www.pmlive.com
Antoine Yver. “While we are disappointed by the outcome of today's…vote, we will work closely with the FDA as it completes the review of our ...
Princeton eatery gives those with intellectual and developmental...
www.nj.com
The restaurant not only provides meals to the Mercer County community, but offers employment to those with intellectual and developmental disabilities.
Trastuzumab deruxtecan achieves ORR of 60.9%
otp.tools.investis.com
Antoine Yver, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo, said: "The strength of the ...
Daiichi-Sankyo-Announces-Appointment-of-Antoine-Yver,-MD,-MSc-to-Globa...
www.quicken.com
Daiichi-Sankyo-Announces-Appointment-of-Antoine-Yver,-MD,-MSc-to-Global-Head,-Oncology-Research-and-Development, Read the latest Daiichi-Sankyo-Co-Ltd...
sortiert nach Relevanz / Datum